Literature DB >> 18985818

Immunogenicity and immunoprotection of recombinant PEB1 in Campylobacter-jejuni-infected mice.

Lian-Feng Du1, Zhen-Jiang Li, Xian-Ying Tang, Jun-Qiong Huang, Wan-Bang Sun.   

Abstract

AIM: To construct a prokaryotic expression vector carrying Campylobacter jejuni peb1A gene and express it in Escherichia coli. Immunoreactivity and antigenicity of rPEB1 were evaluated. The ability of rPEB1 to induce antibody responses and protective efficacy was identified.
METHODS: peb1A gene was amplified by PCR, target gene and prokaryotic expression plasmid pET28a (+) was digested with BamHI and XhoI, respectively. DNA was ligated with T4 DNA ligase to construct recombinant plasmid pET28a(+)-peb1A. The rPEB1 was expressed in E. coli BL21 (DE3) and identified by SDS-PAGE. BALB/c mice were immunized with rPEB1. ELISA was used to detect the specific antibody titer and MTT method was used to measure the stimulation index of spleen lymphocyte transformation.
RESULTS: The recombinant plasmid pET28a (+)-peb1A was correctly constructed. The expression output of PEB1 protein in pET28a (+)-peb1A system was approximately 33% of total proteins in E. coli. The specific IgG antibody was detected in serum of BALB/c mice immunized with rPEB1 protein. Effective immunological protection with a lower sickness incidence and mortality was seen in the mice suffering from massive C. jejuni infection.
CONCLUSION: rPEB1 protein is a valuable candidate for C. jejuni subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985818      PMCID: PMC2761589          DOI: 10.3748/wjg.14.6244

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

1.  Guillain-Barre syndrome with meningoencephalitis after Campylobacter jejuni infection.

Authors:  Takeshi Tsugawa; Koki Nikaido; Toshiaki Doi; Michiaki Koga; Keiichiro Susuki; Tomoki Kubota; Hiroyuki Tsutsumi
Journal:  Pediatr Infect Dis J       Date:  2004-10       Impact factor: 2.129

Review 2.  Campylobacter jejuni in Guillain-Barré syndrome.

Authors:  Richard Hughes
Journal:  Lancet Neurol       Date:  2004-11       Impact factor: 44.182

3.  Mutation in the peb1A locus of Campylobacter jejuni reduces interactions with epithelial cells and intestinal colonization of mice.

Authors:  Z Pei; C Burucoa; B Grignon; S Baqar; X Z Huang; D J Kopecko; A L Bourgeois; J L Fauchere; M J Blaser
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

4.  Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.

Authors:  B C Jacobs; P A van Doorn; P I Schmitz; A P Tio-Gillen; P Herbrink; L H Visser; H Hooijkass; F G van der Meché
Journal:  Ann Neurol       Date:  1996-08       Impact factor: 10.422

5.  Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits.

Authors:  C W Ang; H P Endtz; B C Jacobs; J D Laman; M A de Klerk; F G van der Meché; P A van Doorn
Journal:  J Neuroimmunol       Date:  2000-05-01       Impact factor: 3.478

6.  Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.

Authors:  N Yuki; C W Ang; M Koga; B C Jacobs; P A van Doorn; K Hirata; F G van der Meché
Journal:  Ann Neurol       Date:  2000-03       Impact factor: 10.422

7.  Murine intranasal challenge model for the study of Campylobacter pathogenesis and immunity.

Authors:  S Baqar; A L Bourgeois; L A Applebee; A S Mourad; M T Kleinosky; Z Mohran; J R Murphy
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

Review 8.  Salmonella, Shigella, and Campylobacter: common bacterial causes of infectious diarrhea.

Authors:  H R Stutman
Journal:  Pediatr Ann       Date:  1994-10       Impact factor: 1.132

9.  Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates.

Authors:  S Baqar; A L Bourgeois; P J Schultheiss; R I Walker; D M Rollins; R L Haberberger; O R Pavlovskis
Journal:  Vaccine       Date:  1995-01       Impact factor: 3.641

10.  Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice.

Authors:  S Baqar; L A Applebee; A L Bourgeois
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

View more
  5 in total

1.  A proteome-wide screen of Campylobacter jejuni using protein microarrays identifies novel and conformational antigens.

Authors:  Jiayou Liu; Jodi R Parrish; Julie Hines; Linda Mansfield; Russell L Finley
Journal:  PLoS One       Date:  2019-01-11       Impact factor: 3.240

2.  Comprehensive proteomic profiling of outer membrane vesicles from Campylobacter jejuni.

Authors:  Kyoung-Soon Jang; Michael J Sweredoski; Robert L J Graham; Sonja Hess; William M Clemons
Journal:  J Proteomics       Date:  2013-12-29       Impact factor: 4.044

3.  Microarray-based method for screening of immunogenic proteins from bacteria.

Authors:  Sebastian Hoppe; Frank F Bier; Markus von Nickisch-Rosenegk
Journal:  J Nanobiotechnology       Date:  2012-03-21       Impact factor: 10.435

Review 4.  Advances in Campylobacter biology and implications for biotechnological applications.

Authors:  Byeonghwa Jeon; Wayne T Muraoka; Qijing Zhang
Journal:  Microb Biotechnol       Date:  2009-05-19       Impact factor: 5.813

5.  Rapid identification of novel immunodominant proteins and characterization of a specific linear epitope of Campylobacter jejuni.

Authors:  Sebastian Hoppe; Frank F Bier; Markus von Nickisch-Rosenegk; Markus V Nickisch-Rosenegk
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.